Drugs for Pain: A Clarification | The Medical Letter Inc.

The Medical Letter on Drugs and Therapeutics

FROM
ISSUE

1087

September 18, 2000

View Complete Issue Table of Contents 2019

Drugs for Pain: A Clarification

Show Related
Terms Hide Related
Terms

View Complete Issue

Send Article Feedback

Med Lett Drugs Ther. 2000 Sep 18;42(1087):83-92

Disclosures

Objective(s)

Select a term to see related articles Celebrex celecoxib clarification Coumadin COX-2 inhibitors Drugs for Pain Nonsteroidal anti-inflammatory drugs NSAIDs rofecoxib Vioxx warfarin

SUMMARY: Selective COX-2 Inhibitors and Bleeding Risk: An Additional Note - The Medical Letter article on Drugs for Pain (August 21, 2000) stated that the selective COX-2 inhibitors celecoxib (Celebrex) and rofecoxib (Vioxx) do not inhibit platelet aggregation or bleeding time. Perhaps we should have added, as we did in discussing use of these drugs in rheumatoid arthritis (July 10, 2000), that both celecoxib and rofecoxib, if given with warfarin (Coumadin, and others), increase INR and prothrombin time values and may increase the risk of bleeding.

The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

This article has been freely provided.